Publicaciones en colaboración con investigadores/as de Pfizer (United States) (10)

2021

  1. Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 21, Núm. 5, pp. 1127-1133

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  2. Cost-effectiveness and cost-utility analysis of apixaban versus dabigatran and rivaroxaban in the treatment and secondary prevention of venous thromboembolism

    Pharmacoeconomics - Spanish Research Articles, Vol. 14, Núm. 1, pp. 7-18

2016

  1. Cost-effectiveness analysis of apixaban compared to low-molecular-weight heparins and Vitamin K antagonists for treatment and secondary prevention of venous thromboembolism

    Farmacia Hospitalaria, Vol. 40, Núm. 3, pp. 187-208

2007

  1. Directrices para el desarrollo y la evaluación de guías terapéuticas: Elementos y recomendaciones para su diseño y elaboración

    Medicina Clinica, Vol. 128, Núm. 3, pp. 100-110

  2. Impacto de la EPOC en la vida diaria de los pacientes. Resultados del estudio multicéntrico EIME

    Archivos de Bronconeumologia, Vol. 43, Núm. 2, pp. 64-72

2006

  1. Chronic respiratory symptoms, spirometry and knowledge of COPD among general population

    Respiratory Medicine, Vol. 100, Núm. 11, pp. 1973-1980

2003

  1. A six-month, multicenter, open-label, noncomparative, prospective, observational study of the efficacy and tolerability of atorvastatin in the primary care setting (Estudio del Control de las Hiperlipidemias en Atención Primaria): The CHEAP study

    Current Therapeutic Research - Clinical and Experimental, Vol. 64, Núm. 6, pp. 338-354

  2. Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits

    Clinical Science, Vol. 105, Núm. 6, pp. 655-662

2000

  1. Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits

    General Pharmacology: The Vascular System, Vol. 34, Núm. 4, pp. 263-272